Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.5220
+0.0021 (0.40%)
At close: Nov 13, 2026, 4:00 PM EST
0.5200
-0.0020 (-0.38%)
Pre-market: Nov 16, 2026, 4:20 AM EST

Pasithea Therapeutics Earnings Call Transcripts

Fiscal Year 2026

  • KOL event

    PAS-004 is being evaluated as a once-daily chronic MEK inhibitor for PN and cNFs, two NF1 indications with substantial unmet need. KOLs emphasized tolerability, durable exposure, meaningful response measures, and long follow-up as key to adoption and evaluation.

  • PAS-004 is being tested in NF1, where cutaneous lesions have substantial unmet need and no approved systemic treatment. Initial Phase Ib data are expected next month, with dose selection for expansion targeted around Q1 or Q2 next year.

  • AGM 2026

    The meeting approved the election of two directors, ratified the independent auditors, and authorized a reverse stock split at a flexible ratio. No questions were raised, and all proposals passed by majority vote.

  • Transcript

    PAZ004, a macrocyclic MEK inhibitor, is advancing through clinical trials for NF1 and advanced cancers, showing a differentiated safety and PK profile with promising early efficacy. The program targets significant unmet needs, especially in cutaneous neurofibroma, and is supported by strong patent protection and recent financing.